As the Trump administration’s March 1 deadline for a trade deal with China approaches, with another Xi–Trump summit to follow, it seems almost impossible that a comprehensive agreement will be reached in time. The likely outcome is a punt that defers tariff increases in exchange for ongoing Chinese purchases of U.S. soy and energy.

President Trump and Chinese President Xi Jinping in Beijing, Nov. 9, 2017. Photo: Artyom Ivanov/TASS via Getty Images

The broad contours of China’s current offer have become clearer:

Yes, but: The U.S. wants more structural changes. China apparently hasn’t proposed satisfactory subsidy cuts across China 2025 sectors, nor a credible commitment to scale back informal “buy China” policies. China denies that it requires technology transfers for market access, limiting what it can offer. The U.S., meanwhile, hasn’t offered to buy Huawei equipment or to stop its campaign to dissuade allies from patronizing one of China’s leading companies.

Where it stands: A modest deal that preserves the truce — marked by ongoing talks, the resumption of Chinese purchases of U.S. agricultural goods and a stay on U.S. tariff increases — remains within reach by March 1. That could provide a bridge to a longer-term deal, potentially announced with fanfare at a summit even with key details unresolved.

Between the lines: Further escalation isn’t in the short-run economic interest of either country. Increasing the current 10% tariffs to 25%, as the U.S. threatened, would reduce the purchasing power of U.S. consumers and eat into the profits of U.S. firms with China-centric supply chains. It would effectively be a $30 billion tax hike on the U.S. economy (and more if the scope of the tariffs were broadened).

The bottom line: The prospects of another extension depend on the Trump administration’s endgame — whether rolling back tariffs to maintain the current level of integration, escalating them with a big step toward economic decoupling, or simply holding on through 2020 and leaving the big decisions for a second term or a new president.

Brad Setser is the Steven A. Tananbaum Senior Fellow for International Economics at the Council on Foreign Relations.

Go deeper

Trump says he intends to give RNC speech on White House lawn

President Trump speaking to reporters on South Lawn in July. Photo: Jabin Botsford/The Washington Post via Getty Images

President Trump told the New York Post on Thursday that he plans to deliver his Republican National Convention speech from the White House lawn, despite bipartisan criticism of the optics and legality of the location.

Why it matters: Previous presidents avoided blurring staged campaign-style events — like party conventions — with official business of governing on the White House premises, per Politico.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 7 p.m. ET: 20,739,537 — Total deaths: 751,910— Total recoveries: 12,895,242Map.
  2. U.S.: Total confirmed cases as of 7 p.m. ET: 5,242,184 — Total deaths: 166,971 — Total recoveries: 1,755,225 — Total tests: 64,612,034Map.
  3. Politics: House Democrats to investigate scientist leading "Operation Warp Speed" vaccine projectMcConnell announces Senate will not hold votes until Sept. 8 unless stimulus deal is reached.
  4. 2020: Biden calls for 3-month national mask mandateBiden and Harris to receive coronavirus briefings 4 times a week.
  5. States: Georgia Gov. Brian Kemp to drop lawsuit over Atlanta's mask mandate.
  6. Business: Why the CARES Act makes 2020 the best year for companies to lose money.
  7. Public health: Fauci's guidance on pre-vaccine coronavirus treatments Cases are falling, but don't get too comfortable.

Fauci's guidance on pre-vaccine coronavirus treatments

Illustration: Aïda Amer/Axios

Antibody drugs and various medicine cocktails against the coronavirus are progressing and may provide some relief before vaccines.

The big picture: Everyone wants to know how and when they can return to "normal" life, as vaccines are not expected to be ready for most Americans for at least a year. Two therapies are known to be helpful, and more could be announced by late September, NIAID Director Anthony Fauci tells Axios.